Patents by Inventor Bhawana Bhatt

Bhawana Bhatt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of fibroblast activation protein
    Patent number: 11780821
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: October 10, 2023
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Jennifer Alfaro, Sebastian Belmar, Sebastian Bernales, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20230062022
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: October 1, 2021
    Publication date: March 2, 2023
    Inventors: Son Minh PHAM, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20230047589
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: August 10, 2021
    Publication date: February 16, 2023
    Inventors: Sebastian BERNALES, Luz Marina DELGADO OYARZO, Gonzalo Esteban NÚÑEZ VASQUEZ, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT, Sarvajit CHAKRAVARTY
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220347187
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: August 13, 2020
    Publication date: November 3, 2022
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Jiyun CHEN, Brahmam PUJALA, Bhawana BHATT, Mukesh GANGAR, Amit S. SHETE
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220281859
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: August 13, 2020
    Publication date: September 8, 2022
    Applicant: Nuvation Bio Inc.
    Inventors: Sarvajit CHAKRAVARTY, Son Minh PHAM, Jayakanth KANKANALA, Jiyun CHEN, Brahmam PUJALA, Bhawana BHATT, Mukesh GANGAR, Amit S. SHETE
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20220273659
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: July 1, 2020
    Publication date: September 1, 2022
    Inventors: Son Minh PHAM, Sarvajit CHAKRAVARTY, Jayakanth KANKANALA, Brahmam PUJALA, Amit SHETE, Mukesh GANGAR, Bhawana BHATT, Chris P. MILLER, Jeremy D. PETTIGREW
  • Inhibitors of integrated stress response pathway
    Patent number: 11230542
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: January 25, 2022
    Assignee: PRAXIS BIOTECH LLC
    Inventors: Sebastian Bernales, Luz Marina Delgado Oyarzo, Gonzalo Esteban Núñez Vasquez, Gonzalo Andrés Ureta Díaz, Brahmam Pujala, Dayanand Panpatil, Bhawana Bhatt, Sarvajit Chakravarty
  • Heterocyclic compounds as kinase inhibitors
    Patent number: 11174252
    Abstract: Heterocyclic compounds of Formula (J) as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Grant
    Filed: February 15, 2019
    Date of Patent: November 16, 2021
    Assignee: NUVATION BIO INC.
    Inventors: Son Minh Pham, Sarvajit Chakravarty, Jayakanth Kankanala, Brahmam Pujala, Amit Shete, Bhawana Bhatt, Anil Kumar Agarwal, Sanjeev Soni, Jiyun Chen
  • HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS
    Publication number: 20190248774
    Abstract: Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.
    Type: Application
    Filed: February 15, 2019
    Publication date: August 15, 2019
    Inventors: Son Minh PHAM, Sarvajit CHAKRAVARTY, Jayakanth KANKANALA, Brahmam PUJALA, Amit SHETE, Bhawana BHATT, Anil Kumar AGARWAL, Sanjeev SONI, Jiyun CHEN
  • INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN
    Publication number: 20190185451
    Abstract: Compounds and compositions for modulating fibroblast activation protein (FAP) are described. The compounds and compositions may find use as therapeutic agents for the treatment of diseases, including hyperproliferative diseases.
    Type: Application
    Filed: December 14, 2018
    Publication date: June 20, 2019
    Inventors: Jennifer ALFARO, Sebastian BELMAR, Sebastian BERNALES, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT
  • INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY
    Publication number: 20190177310
    Abstract: The present disclosure relates generally to therapeutic agents that may be useful as inhibitors of Integrated Stress Response (ISR) pathway.
    Type: Application
    Filed: December 13, 2018
    Publication date: June 13, 2019
    Inventors: Sebastian BERNALES, Luz Marina DELGADO OYARZO, Gonzalo Esteban NÚÑEZ VASQUEZ, Gonzalo Andrés URETA DÍAZ, Brahmam PUJALA, Dayanand PANPATIL, Bhawana BHATT, Sarvajit CHAKRAVARTY
  • Heterocyclic compounds and methods of use
    Patent number: 10189826
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: January 29, 2019
    Assignee: Medivation Technologies LLC
    Inventors: Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Bharat Uttam Shinde, Roopa Rai, Son Minh Pham, Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha, Satyanarayana Kallem, Bhawana Bhatt, Vikas Ramdas Bhagwat
  • Heterocyclic Compounds and Methods of Use
    Publication number: 20180051013
    Abstract: This disclosure provides compounds and methods of using those compounds to treat metabolic disorders and hyperproliferative disorders, including administration of the compounds in conjunction with hormone receptor antagonists.
    Type: Application
    Filed: March 4, 2016
    Publication date: February 22, 2018
    Inventors: Brahmam Pujala, Ramniwas Jangir, Rambabu Guguloth, Bharat Uttam Shinde, Roopa Rai, Son Minh Pham, Sebastian Bernales, Jeffrey Lindquist, Mausumee Guha, Satyanarayana Kallem, Bhawana Bhatt, Vikas Ramdas Bhagwat